Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Comments are welcome to point these out. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.
May 28,Jinweike Biotechnology Official WeChat Announcement: ItsIndependently DevelopedFor neovascularAge-related Macular Degeneration(nAMD) Gene Therapy Class I Innovative Drug "JWK001 Injection"Phase I Clinical StudyThe Launch Conference was Successfully Held at West China Hospital of Sichuan University。nAMD is an irreversible ophthalmic disease that seriously affects vision and can even lead to blindness. Its main pathological features include choroidal neovascularization (CNV) or retinal neovascularization in the macular area, and it may also be accompanied by retinal edema as well as retinal exudation, bleeding, scarring, and other changes. Vascular endothelial growth factor (VEGF) has been confirmed to play a significant role in the formation of new blood vessels in nAMD. Currently, wet age-relatedMacular DegenerationHas become the third leading cause of blindness globally after glaucoma and cataracts, with the number of patients worldwide continuously rising.JWK001The injection is the first AAV gene therapy new drug to adopt the "two-plasmid packaging system".JWK001 achieves sustained and efficient expression of anti-VEGF protein in retinal cells by delivering an AAV vector carrying a newly self-designed anti-VEGF protein expression cassette. This gene therapy approach avoids risks associated with traditional nAMD treatments, such as damage to ocular tissues caused by repeated intravitreal injections and poor patient compliance, aiming for a one-time treatment with lifelong effectiveness, offering the potential for a better treatment option for patients.Chengdu Jinweike Biotechnology Co., Ltd.(Abbreviation: Jinweike)Chengdu Jinweike Biotechnology Co., Ltd. is a biotechnology company dedicated to the development of AAV gene therapies for ophthalmic diseases, neuromuscular disorders, and genetic metabolic conditions. Currently, multiple AAV gene therapy products in its pipeline have entered the IIT clinical research stage. The company’s AAV gene therapy products have completed clinical studies involving over 100 patients, demonstrating excellent safety and efficacy data.Source of the article:Jinweike Biotechnology
